Comprehensive genomic sequencing studies have demonstrated that about 2% of patients with RCC have a PGV in a known CSG that is not currently designated as an RCC CSG (e.g. BRCA1, ATM, BRIP1, TP53). This evidence concerns the gene ATM and renal cell carcinoma.